Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth"

TY - JOUR

T1 - Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth"

AU - Radtke, Marc Alexander

AU - Schäfer, Ines

AU - Blome, Christine

AU - Augustin, Matthias

PY - 2013/4/1

Y1 - 2013/4/1

N2 - BACKGROUND: Psoriasis vulgaris is a common disease that follows a chronic course. So far, few studies have addressed outcome methods which evaluate the benefits of drugs and medical devices by measuring patient preferences.OBJECTIVE: Assessment of patients' outcomes using the "Patient benefit index" (PBI), a validated goal attainment scaling tool, in the treatment of psoriasis. Data were obtained within an epidemiological study in 2,009 patients with psoriasis vulgaris and/or psoriatic arthritis.METHODS: Cross-sectional study in 133 nationwide German dermatological practices and hospital departments. The following were recorded a) in the doctors' questionnaire--previous treatments and diseases, clinical characteristics and psoriasis area and severity index (PASI), b) in the patients' questionnaire--quality of life (LQ), patient-relevant therapeutic benefits and satisfaction with care.RESULTS: On average, patients achieved a total PBI of 2.5±1.1. 86.7% of patients showed a more than minimum benefit (PBI>1). Patients treated with biologicals had a higher benefit (mean PBI 3.0) than patients in other groups (e.g. PBI 2.6 in systemics).CONCLUSION: PBI values indicate that systemic agents and biologics are of high therapeutic benefit to the vast majority of patients. The development of the PBI has enabled a decisive step to be taken in the area of scientifically-based outcome assessments.

AB - BACKGROUND: Psoriasis vulgaris is a common disease that follows a chronic course. So far, few studies have addressed outcome methods which evaluate the benefits of drugs and medical devices by measuring patient preferences.OBJECTIVE: Assessment of patients' outcomes using the "Patient benefit index" (PBI), a validated goal attainment scaling tool, in the treatment of psoriasis. Data were obtained within an epidemiological study in 2,009 patients with psoriasis vulgaris and/or psoriatic arthritis.METHODS: Cross-sectional study in 133 nationwide German dermatological practices and hospital departments. The following were recorded a) in the doctors' questionnaire--previous treatments and diseases, clinical characteristics and psoriasis area and severity index (PASI), b) in the patients' questionnaire--quality of life (LQ), patient-relevant therapeutic benefits and satisfaction with care.RESULTS: On average, patients achieved a total PBI of 2.5±1.1. 86.7% of patients showed a more than minimum benefit (PBI>1). Patients treated with biologicals had a higher benefit (mean PBI 3.0) than patients in other groups (e.g. PBI 2.6 in systemics).CONCLUSION: PBI values indicate that systemic agents and biologics are of high therapeutic benefit to the vast majority of patients. The development of the PBI has enabled a decisive step to be taken in the area of scientifically-based outcome assessments.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biological Therapy

KW - Cross-Sectional Studies

KW - Dermatologic Agents

KW - Female

KW - Germany

KW - Humans

KW - Male

KW - Middle Aged

KW - PUVA Therapy

KW - Patient Satisfaction

KW - Psoriasis

KW - Quality of Life

KW - Questionnaires

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1684/ejd.2013.1988

DO - 10.1684/ejd.2013.1988

M3 - SCORING: Journal article

C2 - 23587940

VL - 23

SP - 212

EP - 217

JO - EUR J DERMATOL

JF - EUR J DERMATOL

SN - 1167-1122

IS - 2

ER -